Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 265-272

  Creemers, Esther E ^a   Pinto, Yigal M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Fibrosis; Heart Failure; MiRNAs; TGF

Indexed keywords

MICRORNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; EXTRACELLULAR MATRIX; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE OVERLOAD; HUMAN; INTERSTITIUM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GENE THERAPY; HEART FAILURE; HUMANS; MICRORNAS; MYOCARDIUM; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 78751507979     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq308     Document Type: Article

References (85)

1. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117:568-575.
2. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26: 279-292.
3. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 1999;42:27-44.
4. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 1990;24:741-747.
5. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79:215-262.
6. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
7. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62:757-765.
8. Abrahams C, Janicki JS, Weber KT. Myocardial hypertrophy in Macaca fascicularis. Structural remodeling of the collagen matrix. Lab Invest 1987;56:676-683.
9. Boluyt MO, Bing OH. Matrix gene expression and decompensated heart failure: the aged SHR model. Cardiovasc Res 2000;46:239-249.
10. Grajek S, Lesiak M, Pyda M, Zajac M, Paradowski S, Kaczmarek E. Hypertrophy or hyperplasia in cardiac muscle. Post-mortem human morphometric study. Eur Heart J 1993;14:40-47.
11. Thiedemann KU, Holubarsch C, Medugorac I, Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy. A combined study of morphologic, morphometric, biochemical, and mechanical parameters. Basic Res Cardiol 1983; 78:140-155.
12. Jalil JE, Doering CW, Janicki JS, Pick R, ClarkWA, Abrahams C et al. Structural vs. contractile protein remodeling and myocardial stiffness in hypertrophied rat left ventricle. J Mol Cell Cardiol 1988;20:1179-1187.
13. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 1995;147:29-34.
14. Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L. Collagen expression in mechanically stimulated cardiac fibroblasts. Circ Res 1991;69:116-122.
15. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002;91:1103-1113.
16. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997;96:4065-4082.
17. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001;38: 1227-1232.
18. Detillieux KA, Sheikh F, Kardami E, Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003;57:8-19.
19. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111.
20. Sappino AP, Schurch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990;63:144-161.
21. Flack EC, Lindsey ML, Squires CE, Kaplan BS, Stroud RE, Clark LL et al. Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol 2006;40:474-483.
22. Squires CE, Escobar GP, Payne JF, Leonardi RA, Goshorn DK, Sheats NJ et al. Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol 2005;39: 699-707.
23. Kato S, Spinale FG, Tanaka R, Johnson W, Cooper Gt, Zile MR. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995;269:H863-H868.
24. Bing OH, Fanburg BL, BrooksWW, Matsushita S. The effect of lathyrogen beta-amino proprionitrile (BAPN) on the mechanical properties of experimentally hypertrophied rat cardiac muscle. Circ Res 1978;43:632-637.
25. Miller AD, Tyagi SC. Mutation in collagen gene induces cardiomyopathy in transgenic mice. J Cell Biochem 2002;85:259-267.
26. Weis SM, Emery JL, Becker KD, McBride DJ Jr, Omens JH, McCulloch AD. Myocardial mechanics and collagen structure in the osteogenesis imperfecta murine. Circ Res 2000;87:663-669.
27. MacKenna DA, Omens JH, McCulloch AD, Covell JW. Contribution of collagen matrix to passive left ventricular mechanics in isolated rat hearts. Am J Physiol 1994; 266:H1007-H1018.
28. Schraeger JA, Canby CA, Rongish BJ, Kawai M, Tomanek RJ. Normal left ventricular diastolic compliance after regression of hypertrophy. J Cardiovasc Pharmacol 1994; 23:349-357.
29. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6: 597-641.
30. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787-796.
31. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factorbeta( 1) transgene in the heart. Circ Res 2000;86:571-579.
32. Brooks WW, Conrad CH. Myocardial fibrosis in transforming growth factor beta(1)- heterozygous mice. J Mol Cell Cardiol 2000;32:187-195.
33. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002;283:H1253-H1262.
34. Ikeda H, Inao M, Fujiwara K. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 1996;227:322-327.
35. Hocher B, Godes M, Olivier J, Weil J, Eschenhagen T, Slowinski T et al. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens 2002;20:745-751.
36. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
37. Li JM, Brooks G. Differential protein expression and subcellular distribution of TGFbeta1, beta2 and beta3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol 1997;29:2213-2224.
38. Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbrugg HR, Warnecke C et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 2001;37:1443-1449.
39. Villar AV, Llano M, Cobo M, Exposito V, Merino R, Martin-Duran R et al. Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 2009;46:526-535.
40. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29-.C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-2787.
41. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002;39: 486-492.
42. el-Agroudy AE, Hassan NA, Bakr MA, Foda MA, Shokeir AA, Shehab el-Dein AB. Effect of donor/recipient body weight mismatch on patient and graft outcome in living-donor kidney transplantation. Am J Nephrol 2003;23:294-299.
43. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
44. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-2706.
45. Brand T, Schneider MD. The TGF beta superfamily in myocardium: ligands, receptors, transduction, and function. J Mol Cell Cardiol 1995;27:5-18.
46. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-687.
47. Jayaraman L, Massague J. Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway. J Biol Chem 2000;275:40710-40717.
48. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18: 816-827.
49. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-432.
50. Poncelet AC, Schnaper HW. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem 2001;276:6983-6992.
51. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM et al. Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci USA 1999;96:4844-4849.
52. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA et al. Myocardin-related transcription factor-A controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res 2010;107:294-304.
53. Kagiyama S, Matsumura K, Goto K, Otsubo T, Iida M. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. Regul Pept 2010;160:133-139.
54. Zhao XH, Laschinger C, Arora P, Szaszi K, Kapus A, McCulloch CA. Force activates smooth muscle alpha-actin promoter activity through the Rho signaling pathway. J Cell Sci 2007;120:1801-1809.
55. Wang B, Haldar SM, Lu Y, Ibrahim OA, Fisch S, Gray S et al. The Kruppel-like factor KLF15 inhibits connective tissue growth factor (CTGF) expression in cardiac fibroblasts. J Mol Cell Cardiol 2008;45:193-197.
56. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010;120:254-265.
57. Leenders JJ, Wijnen WJ, Hiller M, van der Made I, Lentink V, van Leeuwen RE et al. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem 2010;285:27449-56.
58. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factorbeta signaling. J Biol Chem 1999;274:8949-8957.
59. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000;6:556-563.
60. Snider P, Standley KN,Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin. Circ Res 2009;105:934-947.
61. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial vs. ventricular fibroblasts: a potential role for platelet-derived growth factor in atrialventricular remodeling differences. Circulation 2008;117:1630-1641.
62. Conway SJ, Molkentin JD. Periostin as a heterofunctional regulator of cardiac development and disease. Curr Genomics 2008;9:548-555.
63. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008;19: 133-144.
64. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000;32:1805-1819.
65. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007;49:1120-1127.
66. Morikawa H, Tamori A, Nishiguchi S, Enomoto M, Habu D, Kawada N et al. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007;13:240-245.
67. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999;13:1774-1786.
68. Lee CH, Shah B, Moioli EK, Mao JJ. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest 2010;120:3340-3349.
69. Ohnishi H, Oka T, Kusachi S, Nakanishi T, Takeda K, Nakahama M et al. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 1998;30:2411-2422.
70. Watsky MA, Weber KT, Sun Y, Postlethwaite A. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int Rev Cell Mol Biol 2010;282:165-192.
71. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol 2009;195: 321-338.
72. Kemp TJ, Aggeli IK, Sugden PH, Clerk A. Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2004;37:603-606.
73. Dziadzio M, Usinger W, Leask A, Abraham D, Black CM, Denton C et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM 2005;98:485-492.
74. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004;27:1164-1170.
75. Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003;130:2779-2791.
76. Panek AN, Posch MG, Alenina N, Ghadge SK, Erdmann B, Popova E et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One 2009;4:e6743.
77. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of micro- RNAs in myocardial matrix remodeling. Circ Res 2009;104:170-178.
78. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-3254.
79. Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009;83:465-472.
80. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
81. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103:18255-18260.
82. Jaffre F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 2009;104:113-123.
83. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82: 21-29.
84. van Rooij E, Sutherland LB, Thatcher JE, Dimaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-13032.
85. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899.